SCHEMBL13256183

SCHEMBL13256183

Cc1cccc(-c2n[nH]c3nc(NC(=O)c4ccccc4)sc23)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.54
KMT2A Q03164 3/20 0.52
MEN1 O00255 1/20 0.52
ADORA2A P29274 3/20 0.51
ADORA3 P0DMS8 2/20 0.51
ADORA1 P30542 2/20 0.51
SCD O00767 1/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
PKM P14618 1/20 0.49
KDR P35968 2/20 0.48
IKBKB O14920 1/20 0.48
MAPK13 O15264 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
EGFR P00533 1/20 0.48
MAPK1 P28482 1/20 0.48
FLT4 P35916 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13256172 0.93 SCD (0.57) MAPK14KMT2AMEN1ADORA2AADORA3
SCHEMBL3501254 0.88 ADORA1 (0.52) MAPK14KMT2AMEN1ADORA2AADORA3
SCHEMBL13256306 0.87 ADORA3 (0.48) KMT2AMEN1ADORA2AADORA3ADORA1
SCHEMBL13256178 0.84 MAPT (0.50) MAPK14KMT2AADORA3NPC1RAB9A
SCHEMBL13256281 0.82 ADORA3 (0.48) KMT2AMEN1ADORA2AADORA3ADORA1
SCHEMBL3500537 0.81 PARP1 (0.54) KMT2AADORA2AADORA3ADORA1SCD
SCHEMBL13256284 0.81 F2 (0.54) KMT2AMEN1ADORA2AADORA3ADORA1
SCHEMBL13256173 0.81 PTGDR2 (0.61) KMT2AMEN1ADORA2AADORA3ADORA1
SCHEMBL13256189 0.80 ADORA3 (0.63) KMT2AMEN1ADORA2AADORA3ADORA1
SCHEMBL13256165 0.80 NPC1 (0.63) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-7473783-B2 Bicyclic pyrazolo protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-01-06 US disclosed
US-7473783-B2 Bicyclic pyrazolo protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS MAP3K20, MAP4K2, MAP4K3 MAPK14 90/4885KMT2A 1583/4885MEN1 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.